The analysis of related bone metabolism indicators in postmenopausal osteoporosis

doi:10.3969/j.issn.1673-8640.2013.08.008

Abstract

Abstract: Objective To observe the changes of the main factor for regulating osteoclast activity and bone resorption and bone formation markers in vivo of patients with postmenopausal osteoporosis(PMOP), and provide the reference for clinical early prevention of osteoporosis. Methods The levels of serum osteoprotegerin(OPG),nuclear factor-k beta receptor activator ligand(RANKL),bone alkaline phosphatase(BAP),serum tartrate-resistant acid phosphatase(TRACP)-5b,estradiol (E2), plasma homocysteine(Hcy) were determined in 38 patients with PMOP, 50 patients with bone mass reducing and 94 subjects with normal bone mass(control group). Partial correlation analysis was used for some of the indicators excluding age and E2. Independent risk factor analysis and binary Logistic regression analysis were used for all indicators. Receiver operating characteristic (ROC) curve evaluation was used for the diagnosis accuracy. Results A statistical significance in E2,Hcy,OPG,RANKL,TRACP-5b and BAP levels was observed in patient groups and control group(P<0.05, P<0.01, P<0.001). BAP levels of PMOP group were higher than those of bone mass reducing and control groups(P<0.001). However, E2 levels were lower than those of bone mass reducing group(P<0.001) and control group(P<0.05). There was no significant difference in E2 and BAP levels between bone mass reducing group and control group(P>0.05). There was a negative correlation between E2 level with TRACP-5b level(r=-0.198, P=0.007)and BAP level (r=-0.157, P=0.035) excluding age. Excluding age and E2, there was a positive correlation between Hcy with RANKL, TRACP-5b and BAP(r=0.368, P<0.001; r=0.193, P=0.009 and r=0.224, P=0.002) and a negative correlation between Hcy with OPG(r=-0.330, P<0.001). There was a negative correlation between OPG and TRACP-5b(r=-0.458, P=0.008), and there was a positive correlation between RANKL and BAP (r=0.228, P=0.044), excluding age and E2. The areas under the ROC curve of E2, Hcy, OPG, RANKL, TRACP-5b and BAP for the diagnosis of osteoporosis were 0.819, 0.686, 0.803, 0.776, 0.731 and 0.719, respectively. The Logistic regression analysis showed that E2, OPG, TRACP-5b and Hcy had evident effect to osteoporosis excluding age, which the odd ratios(OR) were 0.901, 0.046, 4.165 and 9.112, respectively. Conclusions TRACP-5b, Hcy and BAP are better for the diagnosis of osteoporosis, and they can be used as the reference for the clinical early prevention of PMOP.

Key words: Osteoprotegerin, Nuclear factor-k beta receptor activator ligand, Bone alkaline phosphatase, Tartrate-resistant acid phosphatase, Estradiol, Homocysteine, Bone metabolism, Postmenopausal osteoporosis

CLC Number:

R446.1

YANG Lishun,YUAN Haisheng,SHEN Xingya,KANG Jianhua,WANG Aiyun.. The analysis of related bone metabolism indicators in postmenopausal osteoporosis[J]. , 2013, 28(8): 685-689.

References

[1] 易伟莲,廖德权,林柏云,等.绝经后骨质疏松症患者性激素、细胞因子及骨代谢指标的变化及关系[J]. 检验医学,2012,27(4):296-298.

[2] 白旭华.雌激素与绝经后骨质疏松症关系的研究进展[J]. 内蒙古民族大学学报(自然科学版),2007,29(2):180-182.

[3] 安胜军,杨学辉,李恩.雌激素与骨质疏松症[J].中国骨质疏松杂志,1999,5(3):77-85.

[4] 梁少俊,刘宏,杨力,等.绝经后骨质疏松与血清OPG及RANKL关系的研究[J]. 广东医学,2006,27(5):669-671.

[5] Yano K,Tsuda E,Washida N,et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis[J]. J Bone Miner Res,1999,14(4):518-527.

[6] Rogers A,Saleh G,Hannon RA,et al. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women[J]. J Clin Endoerinol Metab,2002,87(10):4470-4475.

[7] Mezquita-Raya P, de la Hiquera M, García DF, et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women[J]. Osteoporos Int, 2005,16(11):1368-1374.

[8] Hobfauer LC,Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology[J]. J Mol Med(Berl),2001,79(5-6):243-253.

[9] Zheng SX,Vrindts Y,Lopez M,et al. Increase in cytokine production (IL-1 beta,IL-6,TFN-alpha but not INF-gamma,GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis[J]. Maturitas,1997,26(1):63-71.

[10] Hodgson SF,Watts NB,Bilezikian JP,et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis : 2001 edition, with selected updates for 2003[J]. Endocr Pract,2003,9(6):544-564.

[11] Sato Y, Iwamoto J,Kanoko T,et al. Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson′s disease[J]. Am J Med,2005,118(11):1250-1255.

[12] McLean RR,Jacques PF,Selhub J,et al. Homocysteine as a predictive factor for hip fracture in older persons[J]. N Engl J Med,2004,350(20): 2042-2049.

[13] Van Meurs JB,Dhonukshe-Rutten RA,Pluijm SM,et al . Homocysteine levels and the risk of osteoporotic fracture[J]. N Engl J Med,2004,350(20): 2033-2041.

[14] 赖欧杰,沈彬.同型半胱氨酸与骨质疏松症的关系[J].中国骨质疏松杂志,2009,15(8):625-628.

[15] 曾芳馨,熊中云. 抗酒石酸酸性磷酸酶与骨代谢[J].华西医学, 2005,20 (3):545.

[16] 肖恩,孟萍.骨质疏松骨代谢生化指标的研究进展[J]. 中国骨质疏松杂志,2008,14(3):212-216.